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ABSTRACT
Aim To compare 24 h intraocular pressure (IOP) control
obtained with preservative free (PF) taﬂuprost 0.0015%
versus branded preservative containing latanoprost
0.005% administered as ﬁrst choice monotherapy in
patients with primary open angle glaucoma (POAG) or
ocular hypertension (OHT).
Methods This prospective, observer-masked, crossover
study included consecutive newly diagnosed patients
with POAG or OHT, and baseline IOP between 24 and
33 mm Hg. Qualifying patients underwent baseline
untreated 24 h IOP monitoring in habitual positions,
with Goldmann tonometry at times 10:00, 14:00, 18:00
and 22:00, and Perkins supine tonometry at times 02:00
and 06:00. They were then randomised to either
latanoprost or taﬂuprost, administered in the evening, for
3 months and then switched to the opposite therapy for
another 3 months. 24 h monitoring was repeated at the
end of each treatment period.
Results 38 patients completed the study. Mean
untreated 24 h IOP (24.9 mm Hg) was signiﬁcantly
reduced with both prostaglandins (p<0.001). Taﬂuprost
demonstrated similar mean 24 h efﬁcacy compared with
latanoprost (17.8 vs 17.7 mm Hg; p=0.417).
Latanoprost demonstrated signiﬁcantly better 24 h
trough IOP (15.9 vs 16.3 mm Hg; p=0.041) whereas
taﬂuprost provided signiﬁcantly lower 24 h IOP
ﬂuctuation (3.2 vs 3.8 mm Hg; p=0.008). No signiﬁcant
difference existed between the two prostaglandins for
any adverse event.
Conclusions PF taﬂuprost achieved similar 24 h IOP
reduction to branded latanoprost. The current study
highlights the importance of complete assessment of
efﬁcacy over 24 h.
Clinical trials registration NCT01162603.
INTRODUCTION
Prostaglandin analogues have become a popular
ﬁrstline therapeutic option for the decrease in
intraocular pressure (IOP) in patients with open
angle glaucoma or ocular hypertension (OHT) due
to their superior 24 h potency, convenient dosing
and favourable systemic safety proﬁle. Until
recently, all available prostaglandin analogues were
formulated as preservative containing solutions.
Preservatives used in ophthalmic solutions, and in
particular benzalkonium chloride (BAK), have been
associated with ocular tissue toxicity and decreased
long term tolerability, thus potentially limiting
adherence and undermining the success of chronic
medical therapy.1–5 Long term tolerability has
emerged as a key issue for the successful manage-
ment of glaucoma patients. Furthermore, there is
growing recognition that preservatives are asso-
ciated with ocular surface disease, which negatively
impacts on quality of life in glaucoma patients.6
Taﬂuprost 0.0015% is a relatively new prosta-
glandin analogue that ﬁrst became commercially
available as a BAK preserved formulation. The ﬁrst
studies indicated that the IOP lowering effect of
preserved taﬂuprost is comparable, or slightly infer-
ior, to that of latanoprost7 8 and travoprost.9 More
recently, a preservative free (PF) formulation of
taﬂuprost has been made available in several coun-
tries worldwide.10–17 The comparative efﬁcacy of
PF taﬂuprost versus other prostaglandins needs to
be further elucidated in controlled prospective
studies.
To date, the 24 h efﬁcacy of PF taﬂuprost has
not been determined. In order to select the optimal
initial monotherapy, it is important to compare the
efﬁcacy of all available prostaglandin analogues
over 24 h. Therefore, the present investigation eval-
uated the 24 h IOP efﬁcacy of PF taﬂuprost
0.0015% versus BAK preserved branded latano-
prost 0.005% when both were administered as ﬁrst
choice therapy in patients with primary open angle
glaucoma (POAG) or OHT.
MATERIALS AND METHODS
The research protocol adhered to the tenets of the
Declaration of Helsinki and was approved by the
institutional review boards of the participating
centres. Written informed consent was obtained
from all participants prior to enrolment. The trial
was registered at clinicaltrials.gov (NCT01162603).
Consecutive adults with newly diagnosed POAG
or OHTwere recruited at two participating centres.
Eligible subjects had to exhibit untreated sitting
morning IOP, evaluated with Goldmann tonometry,
of 24–33 mm Hg in the study eye on two separate
baseline IOP measurements performed at time
10:00 (±1 h). Additional eligibility criteria were
central corneal thickness between 500 and 600 μm
and age 39–85 years. In each case, the diagnosis of
POAG or OHTwas made by one of two glaucoma
specialists (AGPK or LQ) based on the European
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Glaucoma Society criteria following a comprehensive clinical
examination.
Exclusion criteria for ophthalmic conditions were corneal or
other anatomical abnormalities preventing reliable applanation
tonometry, severe dry eye, use of contact lenses, intolerance or
contraindication to latanoprost, taﬂuprost or BAK, history of
poor medication adherence, laser treatment or ocular surgery of
any type in the study eye, best corrected visual acuity less than
Snellen 0.1, mean deviation worse than −12 dB on Humphrey
24–2 SITA standard perimetry, cup to disc ratio >0.8, or the
possibility of optic nerve damage and visual function deterior-
ation due to study procedures according to the investigator’s
judgment. Exclusion criteria for systemic conditions were preg-
nancy or lactation, unwillingness to avoid pregnancy and use of
corticosteroids within the 2 months before enrolment.
Procedures
The trial was designed as a prospective, randomised, observer
masked, active controlled, crossover study. First, eligible partici-
pants were admitted at the participating academic centres and
underwent baseline untreated 24 h IOP monitoring in habitual
positions, with Goldmann sitting tonometry, at times 10:00,
14:00, 18:00 and 22:00, and Perkins supine tonometry at times
02:00 and 06:00 (±1 h). In each centre, the same calibrated
Goldmann and Perkins tonometers were used for all measure-
ments. In all cases, the investigator who performed the IOP
measurements was blinded to the treatment regimen. Following
the untreated 24 h IOP curve, participants were randomised to
either 3 months of chronic therapy with preserved latanoprost
0.005% solution (Xalatan; Pﬁzer) dosed in the evening (20:00),
or to 3 months of therapy with PF taﬂuprost 0.0015% solution
(Saﬂutan; MSD) dosed also in the evening (20:00). Both eyes
were treated. Instructions regarding correct eyedrop instillation
and adherence were also provided. At the end of this initial 3
month treatment period, all participants underwent a treated 24
h IOP assessment, as previously described. Patients were then
crossed over to the opposite prostaglandin therapy for another
3 months and instructions regarding correct eyedrop instillation
and adherence were repeated. At the end of this ﬁnal therapy
period, participants underwent a third 24 h IOP curve with
identical methodology. A comprehensive clinical examination
was performed at all visits. Additionally, patient reported com-
plains and symptoms, as well as investigator noted adverse
events, were recorded at the end of each treatment period.
Statistics
The primary efﬁcacy endpoint for this study was mean 24 h
IOP. Individual time points, peak, trough and ﬂuctuations in 24
h IOP were evaluated as secondary endpoints. The study had
80% power to identify a 1.25 mm Hg difference between indi-
vidual time points and between the mean 24-h IOP, assuming an
SD of 2.8 mm Hg between the two prostaglandin monother-
apies. One randomly selected eye per participant was analysed.
A mixed model was used for the crossover repeated measures
design to adjust for period and carryover effects.18 Additionally,
the model was adjusted for the centre effect. A 95% CI was
constructed for the adjusted difference in means. An intention
to treat approach was adopted, and subjects were analysed
according to their randomised group.
To correct for multiple comparisons at individual time points,
a Bonferroni adjustment was used. Thus Bonferroni adjusted p
values are reported for individual time point comparisons. All
other reported p values are two tailed, with p<0.05 considered
signiﬁcant. Mean 24 h IOP ﬂuctuation was deﬁned as the
average of the difference between the highest IOP reading
minus the lowest IOP reading within the 24 h curve for each
patient. Adverse events were evaluated using a McNemar test.
All analyses were conducted using IBM-SPSS 20.0.
RESULTS
Patients
Thirty-eight of 40 enrolled participants completed the study.
Their ﬂowchart and demographics are presented in ﬁgure 1 and
table 1. Two study patients (one in each therapy group) were
lost to follow-up.
Intraocular pressure
Compared with untreated baseline readings, mean 24 h, peak,
trough, ﬂuctuation and IOP at individual time points were all
signiﬁcantly reduced with both prostaglandin monotherapies
(p<0.001 for all comparisons) (table 2). When the two prosta-
glandins were directly compared, PF taﬂuprost demonstrated
similar mean 24 h efﬁcacy compared with preserved latanoprost
(17.8±2.2 vs 17.7±2.1 mm Hg; p=0.417). Furthermore, there
Figure 1 Flowchart of the study participants.
Table 1 Participant demographics
Characteristic
Sex (M/F) 18/20
Age (years) 66.7 (9.1)
CCT (μm) 551 (24.4)
Snellen BCVA 0.8 (0.2)
C/D 0.6 (0.1)
MD (dB) 5.41 (3.1)
Values are mean (SD) or number.
BCVA, best corrected visual acuity; CCT, central corneal thickness; C/D, cup/disc ratio;
MD, mean deviation.
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were no statistically signiﬁcant differences for individual time
points (table 2, ﬁgure 2).
With regard to other 24 h IOP characteristics, PF taﬂuprost
demonstrated signiﬁcantly lower 24 h IOP ﬂuctuation (3.2±1.7
vs 3.8±1.8 mm Hg; p=0.008). In contrast, latanoprost pro-
vided signiﬁcantly lower 24 h trough IOP (15.9±2.1 vs 16.3
±2.2 mm Hg; p=0.041). There was no signiﬁcant difference in
24 h peak IOP between the two prostaglandins (19.7 vs
19.5 mm Hg, respectively; p=0.277) (table 2).
Adverse events
No serious adverse events and no adverse event related with-
drawal occurred during the study. In addition, there was no sig-
niﬁcant difference between the two agents for any adverse event
(table 3). Overall, the number of adverse events with latanoprost
and PF taﬂuprost treatment were 22 and 14, respectively. The
most frequently encountered adverse event was ocular hyper-
aemia (n=6 during latanoprost treatment period; n=5 during
PF taﬂuprost treatment period).
DISCUSSION
The present study is the ﬁrst to evaluate the 24 h efﬁcacy of PF
taﬂuprost compared with branded preserved latanoprost as a
ﬁrst choice monotherapy in newly diagnosed patients with
POAG or OHT. The results showed identical mean IOP lower-
ing over 24 h (mean 24 h IOP difference was only 0.1 mm Hg).
Greater 24 h trough IOP reduction was observed during latano-
prost therapy while signiﬁcantly lower 24 h IOP ﬂuctuation was
documented with PF taﬂuprost.
Taﬂuprost, a ﬂuorinated analogue of prostaglandin F2a, is a
potent and selective agonist of the human prostanoid FP recep-
tor with a reported 12 fold greater afﬁnity for the FP receptor
than latanoprost.19 It was ﬁrst introduced in Japan in 2008 as a
BAK containing multidose formulation, and in Germany in
2008 with approval for both a preserved and a PF taﬂuprost for-
mulation.20 21 Currently, however, throughout the rest of the
world, only the PF formulation is marketed.20 21 Initial reports
in healthy eyes indicated that preserved taﬂuprost was at least as
well tolerated and safe as preserved latanoprost when used over
short periods.22–25 Furthermore, it was demonstrated that the
efﬁcacy of preserved taﬂuprost was comparable with that of pre-
served latanoprost in healthy volunteers.22–26
Due to its short marketing history, there are limited long term
efﬁcacy data for preservative containing taﬂuprost in patients
with glaucoma or OHT. Two studies have reported that pre-
served taﬂuprost attained a mean diurnal IOP reduction of
28.6% and 29.1%, respectively, from untreated baseline.8 9 A
third short term phase II study7 reported that the mean IOP
change from baseline of preserved taﬂuprost was similar to that
of branded latanoprost after 42 days (−9.7 mm Hg for taﬂuprost
and −8.8 mm Hg for latanoprost). In a 24 month, parallel,
double blind, multicenter study performed by Uusitalo et al,8
taﬂuprost lowered daytime IOP by 6–8 mm Hg (27–31%) com-
pared with 7–9 mm Hg (29–35%) with branded latanoprost. In
this study, after 24 months of therapy, the mean decrease in IOP
from baseline was reported to be somewhat superior with lata-
noprost (−7.7 mm Hg, 32.2%) than preserved taﬂuprost
Figure 2 Intraocular pressure (mean±95% CI) at each individual time
point and for the 24 h pressure at baseline (gray solid line), in the
latanoprost (solid black line) and preservative free (Pf ) taﬂuprost (black
dotted line) treatment groups.
Table 2 Intraocular pressure results at baseline and after treatment with the study medications
IOP measurements (time)
Baseline
(mean (95% CI))
Latanoprost
(mean (95% CI))*
PF tafluprost
(mean (95% CI))* Adjusted difference (mean (95% CI))* p Value
06:00 25.1 (24.2 to 26.0) 17.5 (16.7 to 18.3) 17.5 (16.8 to 18.4) 0.00 (−0.44 to 0.44) 1.000†
10:00 26.9 (26.1 to 27.7) 17.9 (17.0 to 18.8) 18.4 (17.5 to 19.3) −0.50 (−1.03 to 0.03) 0.372†
14:00 24.1 (23.2 to 25.0) 17.3 (16.5 to 18.2) 17.8 (17.0 to 18.6) −0.47 (−1.05 to 0.10) 0.624†
18:00 23.8 (23.0 to 24.6) 17.3 (16.4 to 18.1) 17.7 (16.8 to 18.5) −0.39 (−0.88 to 0.09) 0.648†
22:00 24.9 (23.8 to 26.0) 17.8 (16.9 to 18.8) 17.6 (16.6 to 18.5) 0.24 (−0.20 to 0.67) 1.000†
02:00 24.4 (23.6 to 25.2) 18.0 (17.2 to 18.9) 17.6 (16.8 to 18.4) 0.45 (−0.07 to 0.96) 0.516†
Mean 24 h 24.9 (24.2 to 25.5) 17.7 (16.9 to 18.4) 17.8 (17.0 to 18.5) −0.11 (−0.39 to 0.17) 0.416
Peak 24 h 27.7 (26.8 to 28.6) 19.7 (18.8 to 20.5) 19.5 (18.6 to 20.3) 0.24 (−0.18 to 0.66) 0.277
Trough 24 h IOP 18.3 (17.8 to 18.8) 15.9 (15.2 to 16.6) 16.3 (15.6 to 17.0) −0.39 (−0.78 to −0.01) 0.041
24 h fluctuation 3.7 (3.4 to 4.0) 3.8 (3.2 to 4.3) 3.2 (2.6 to 3.7) 0.63 (0.18 to 1.08) 0.008
Depicted p values refer to comparison between latanoprost and PF tafluprost. All comparisons between baseline and latanoprost or preservative free tafluprost were statistically
significant (p<0.001).
*Adjusted for period, carryover effect and centre.
†Bonferroni adjusted p values.
IOP, intraocular pressure; PF, preservative free.
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(−7.1 mm Hg, 29.1%).8 This study demonstrated that the non-
inferiority criterion for taﬂuprost was reached with ANOVA and
almost reached with ANCOVA for all daytime IOP
measurements.
There is convincing evidence suggesting that PF taﬂuprost
exhibits comparable efﬁcacy to preserved taﬂuprost. First, a
pharmacokinetic study27 did not detect a difference in systemic
bioavailability between the two formulations after 8 days.
Second, Hamacher et al10 evaluated the IOP lowering equiva-
lency between the two formulations and observed an overall
efﬁcacy difference of only 0.01 mm Hg (95% CI −0.46 to 0.49;
p=0.96) at 4 weeks.
Several open label non-interventional studies have examined
the efﬁcacy and tolerability of PF taﬂuprost in naïve16 or previ-
ously treated patients with open angle glaucoma or OHT, who
were either poorly controlled or had tolerability issues with
other medications.12–15 28 Overall, these investigations have
reported a mean diurnal IOP reduction of 22.9–32.1% from
untreated baseline.13 16 28 Although these studies do not
provide controlled observations, they indicate that PF taﬂuprost
has almost comparable efﬁcacy to latanoprost and will likely
beneﬁt patients facing tolerability problems with other medica-
tions. Similar IOP results were reported in a prospective investi-
gator masked study.29 In a more recent regulatory double
masked comparative trial, Chabi et al11 demonstrated in patients
with open angle glaucoma or OHT that PF taﬂuprost was gener-
ally well tolerated and was not inferior to PF timolol adminis-
tered twice daily.
The current trial investigated for the ﬁrst time the 24 h IOP
efﬁcacy provided by a PF taﬂuprost versus branded latanoprost,
a well established initial therapy of choice. Both agents provided
clinically meaningful 24 h IOP reduction from baseline (28.5%
for PF taﬂuprost and 29.3% for latanoprost). These results are
comparable with the reported 24 h efﬁcacy of the three previ-
ously available prostaglandin analogues, as reported in a
meta-analysis by Stewart et al (24–29%).30 A 24 h IOP curve
may better delineate IOP characteristics and facilitate glaucoma
management. Thus our study provides evidence to optimise
selection between available prostaglandin analogues as initial
therapy.
This efﬁcacy proﬁle would not have been detected without a
complete 24 h IOP evaluation. Thus the present study highlights
the value of a complete efﬁcacy assessment over 24 h in deter-
mining the true IOP lowering characteristics of a novel antiglau-
coma medication. In a previous 24 h IOP study in 30 healthy
Japanese subjects, Mochizuki et al compared the efﬁcacy of
taﬂuprost and branded latanoprost.25 Apart from the differences
in study populations and despite several methodological differ-
ences (timing of drug administration, duration of therapy and
different time of IOP measurements), it is interesting to note the
similarities in ﬁndings between the two 24 h studies. The
Mochizuki study25 also observed a mean 24 h difference of
0.1 mm Hg and the two prostaglandins exhibited similar ten-
dencies to preferentially lower IOP during the day (latanoprost)
and night (taﬂuprost). In contrast with the present study,
however, these IOP lowering differences reached statistical sig-
niﬁcance in the Japanese study.
In the present study, PF taﬂuprost achieved signiﬁcantly less
24 h IOP ﬂuctuation than branded latanoprost. Twenty-four
hour IOP ﬂuctuation and 24 h peak IOP have emerged in some
24 h studies31–33 as potential risk factors for glaucoma progres-
sion. This has brought attention to the 24 h IOP lowering
Table 3 Adverse events of the study medications
Adverse event Latanoprost
PF tafluprost n (%)
p ValueYes No Total
Ocular hyperaemia Yes 2 4 6 (15.8) 1.000
No 3 29 32 (84.2)
n (%) Total 5 (13.2) 33 (87.8) 38 (100)
Stinging Yes 1 3 4 (10.5) 1.000
No 3 31 34 (89.5)
n (%) Total 4 (10.5) 34 (89.5) 38 (100)
Foreign body sensation Yes 0 2 2 (5.3) 1.000
No 2 34 36 (94.7)
n (%) Total 2 (5.3) 36 (94.7) 38 (100)
Blurring of vision Yes 1 3 4 (10.5) 0.250
No 0 34 34 (89.5)
n (%) Total 1 (2.6) 37 (97.4) 38 (100)
Watering Yes 1 1 2 (5.3) 1.000
No 0 36 36 (94.7)
n (%) Total 1 (2.6) 37 (97.4) 38 (100)
Itchiness Yes 0 2 2 (5.3) 0.500
No 0 36 36 (94.7)
n (%) Total 0 (0) 38 (100) 38 (100)
Burning Yes 0 2 2 (5.3) 0.500
No 0 36 36 (94.7)
n (%) Total 0 (0) 38 (100) 38 (100)
Ocular ache Yes 0 0 0 (0) 1.000
No 1 37 38 (100)
n (%) Total 1 (2.6) 37 (97.4) 38 (100)
PF, preservative free.
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proﬁles with topical medications.34 35 Based on the notion that
increased circadian IOP ﬂuctuation may be harmful for some
glaucoma patients, it may be clinically desirable to opt for
favourable 24 h IOP characteristics, such as low 24 h IOP ﬂuc-
tuation and low 24 h peak IOP. However, the potential long
term clinical beneﬁt of improved 24 h IOP control requires
further elucidation.
The current study was a short term monotherapy study and it
did not have sufﬁcient power to determine long term safety or
tolerability. Both medications were well tolerated without
serious adverse events or adverse event related study withdra-
wals. There was no signiﬁcant difference in the incidence of
individual adverse events. Nevertheless, the adverse events
observed in our trial may not accurately portray the true long
term tolerability proﬁle of these agents.
Glaucoma requires lifelong treatment and thus long term toler-
ability is an issue of clinical importance. Cumulative evidence
shows that long term topical treatment with antiglaucoma medica-
tions leads to the manifestation, or exacerbation, of symptoms and
signs of ocular surface disease.3 36 As a consequence, patient’s
quality of life can decline and adherence may be adversely
affected.37–42 There is convincing evidence that long term exposure
to preservatives, and especially BAK, can cause histopathological
changes in ocular tissues that can adversely affect the success of sub-
sequent glaucoma surgery.4 5 PF medications have become increas-
ingly popular in glaucoma due to their reduced potential for ocular
toxicity with presumed enhanced tolerability and improved adher-
ence.1 38 43 44 The observation of similar drug efﬁcacy versus avail-
able preservative containing treatment options may encourage
greater use of PF medications. On the other hand, more evidence is
needed to conﬁrm the long term potential beneﬁts accrued with
the use of PF medications, such as improved medication adherence
leading to better long term visual outcomes. By demonstrating
comparable 24 h efﬁcacy to branded latanoprost, PF taﬂuprost can
be considered as a reasonable ﬁrstline choice in glaucoma therapy.
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